Regeneron Pharmaceuticals, Inc. (REGN) stock prices updated...
 

Regeneron Pharmaceuticals, Inc. stock price

Regeneron Pharmaceuticals, Inc. latest news:


  • 11/08/2017 05:50:01

    Regeneron's stock rallies after profit and sales rise above expectations

    Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased to $388.3 million, or $3.32 a share, from $264.8 million, or $2.27 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.99, beating the FactSet consensus of $3.82. Revenue rose to $1.50 billion from $1.22 billion, above the FactSet consensus of $1.45 billion, as net product sales, Sanofi collaboration revenue and Bayer collaboration revenue all beat expectations. Sales of its lead retinal therapy Eylea rose 12% to $953 million, beating the FactSet consensus of $935 million. The stock has fallen 14% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has slipped 0.1% and the S&P 500 has gained 4.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/16/2017 16:16:14

    CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

    Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

  • 09/11/2017 14:32:16

    Federated, Carnival, Alphabet climb; Regeneron skids

    Federated National Holding, Carnival and Alphabet rise while Regeneron Pharmaceuticals trades lower

  • 09/10/2017 23:15:57

    BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

    Regeneron Pharmaceuticals Inc(REGN). * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Co, Sanofi announced pivotal phase 3 liberty asthma quest study of met its two primary endpoints.

  • 08/30/2017 09:29:54

    Biotech stocks rally, ETF on track for third straight daily gain

    Biotechnology stocks rallied on Wednesday, with one of the biggest exchange-traded funds dedicated to the sector on track for its third straight daily advance. The iShares Nasdaq Biotechnology ETF gained 1.3%, bringing its week-to-date rise to 3.6%. Among the biggest gainers in the sector, Gilead Sciences Inc. popped 5.6%, bringing its gain over the past three months to 23.7%. The stock is on track for its largest percentage gain since November, as well as its highest close since September 2016. Separately, Incyte Corp. added 4.5% while BioMarin Pharmaceutical Inc. advanced 4.8%. Biogen Inc. gained 2.4% while Regeneron Pharmaceuticals Inc. was up 2%. On the downside within the pharmaceutical sector, U.S.-listed shares of Novartis AG were down 1%. The company's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Regulus Therapeutics Inc.RGLS | Reis, IncREIS | Reliv'' International, Inc.RELV | Relypsa, Inc.RLYP | Remark Media, Inc.MARK | Remy International, Inc.REMY | Renasant CorporationRNST | Renewable Energy Group, Inc.REGI | Rent-A-Center Inc.RCII | Rentech, Inc.RTK |